AZD3480 (TC-1734) FOR THE TREATMENT OF ADULT ADHD

AZD3480 (TC-1734) 用于治疗成人多动症

• 批准号: 7952128
• 负责人: ALEXANDRA S POTTER
• 金额: $ 3.08万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952128
• 关键词: Acetylcholine; Adolescence; Adult; Adverse effects; Attention deficit hyperactivity disorder; Brain; Chemicals; Child; Childhood; Clinical Research; Cognitive; Cognitive deficits; Computer Retrieval of Information on Scientific Projects Database; Diagnosis; Funding; Grant; Human; Institution; Mental disorders; Neurobehavioral Manifestations; Performance; Pharmaceutical Preparations; Pilot Projects; Research; Research Personnel; Resources; Ritalin; Source; Symptoms; System; United States National Institutes of Health; Work; cholinergic; improved; psychostimulant

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Attention Deficit/Hyperactivity Disorder (ADHD) is one of the most common childhood psychological disorders. While ADHD first appears in childhood the symptoms persist into adolescence and adulthood for up to 80% of people who are diagnosed as children. The current medications to treat ADHD are the psychostimulants (such as Ritalin). These medications are not effective for all people with ADHD and some people have side effects to these medications. Research has demonstrated that a different type of drug, ones that increase the amount of acetylcholine (a naturally occurring chemical in your brain) can also alleviate some of the symptoms of ADHD and also improve some of the cognitive deficits in ADHD. However there are no approved cholinergic treatments for ADHD. TC-1734 is a new drug which works on the cholinergic system and shows cognitive benefits in pilot studies in humans. This is a pilot study to determine the effects of TC1734 on the symptoms and cognitive performance in adults with ADHD.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 注意缺陷/多动症（ADHD）是最常见的儿童心理障碍之一。 虽然ADHD首次出现在童年时期，但症状持续到青春期和成年期，多达80％被诊断为儿童。 当前治疗多动症的药物是精神刺激剂（例如利他林）。 这些药物对所有多动症患者无效，有些人对这些药物有副作用。 研究表明，增加乙酰胆碱量（一种天然存在的化学物质）的药物也可以减轻ADHD的某些症状并改善ADHD中的某些认知缺陷。 但是，没有针对多动症的授权胆碱能疗法。 TC-1734是一种在胆碱能系统上起作用的新药，并在人类的试点研究中显示出认知益处。 这是一项试点研究，旨在确定TC1734对ADHD成人症状和认知表现的影响。